Targeted blood proteome profiling using NULISAseq identifies a high‐performance biomarker panel for Aβ pathology quantification and staging
This study provides a systematic profile of dynamic protein alterations during Aβ pathology progression. Moreover, we developed a biomarker assay that accurately quantifies Aβ pathology, offering a potential tool to facilitate early screening and monitoring of amyloid pathology.
Authors
- Wan Wa Wong
- Yuanbing Jiang (ORCID: https://orcid.org/0000-0001-8585-0714)
- Nancy Y. Ip
- Wenyue Zheng (ORCID: https://orcid.org/0000-0002-1087-1972)
- Timothy C Y Kwok
- W Wong
- Yat Fung Shea
- Vincent C. T. Mok
- Kin Ying Boniface MOK
- Henrik Zetterberg
- Hiu Yi Wong
- Fanny C. Ip
- Ronnie M. N. Lo
- John Hardy
- Lily K. W. Cheng
- Amanda Heslegrave
- Elaine Y. L. Cheng
- Bonnie W. Y. Wong
- Chun Keung Shum
- Jacqueline K. Y. Yuen
- Siu Ki Leung
- Hok Man Wai
Institutions
- Department of Health (CN)
- Chinese University of Hong Kong (HK)
- Tuen Mun Hospital (CN)
- Sahlgrenska University Hospital (SE)
- United Christian Hospital (CN)
- HKUST Shenzhen Research Institute (CN)
- Institute for Neurodegenerative Disorders (US)
- UK Dementia Research Institute (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Gothenburg (SE)
- University of Hong Kong (HK)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1002/alz.71179
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Queen Mary University of London
- European Commission
- Innovation and Technology Commission
- Vetenskapsrådet
- Chinese University of Hong Kong
- Hong Kong University of Science and Technology
- HORIZON EUROPE Framework Programme